Poxel S.A.

Poxel S.A.

PXXLF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$9.39M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Poxel S.A.Poxel S.A.-0.4-74%--1

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$9.39 Million
Enterprise Value$69.35 Million
Earnings per Share$-0.42
Beta1.28
Outstanding Shares42,694,000

Return

Return on Equity74.19%ROE
Return on Assets-910.92%
Return on Invested Capital105.79%

Valuation & Multiples

P/E Ratio-0.38P/E Ratio
PEG-0.25PEG
Price to Sales-Price to Sales
Price to Book Ratio-0.11Price to Book Ratio
Enterprise Value to Revenue4.84
Enterprise Value to EBIT-4.71
Enterprise Value to Net Income-2
Total Debt to Enterprise0.89
Debt to Equity-1.01Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
September 23, 2026
EPS Estimate
-
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Next Earnings Call

Expected Date
March 24, 2027
EPS Estimate
-
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Poxel S.A.

5 employees
CEO: Yves Decadt

Poxel S.A. is a clinical-stage biopharmaceutical firm dedicated to discovering innovative therapies for a range of conditions, including metabolic disorders, type 2 diabetes, and liver ailments. Its most advanced investigational drug, Im...